So-called Crossover Funds are finding little opportunity to invest in medtech companies with short paths to the public markets, but Robert C. Faulkner, Redmile Group, and Steve Hochberg, Deerfield Management, still see opportunities in Medtech. Lisa Earnhardt, CEO of IntersectENT, leads a discussion between the two.
Lisa Earnhardt, President & CEO – Intersect ENT
Lisa Earnhardt leads Intersect ENT (NASDAQ: XENT), a medical technology company dedicated to improving the quality of life for patients with ear, nose and throat conditions having led the company from the early clinical stage.
Rob joined Redmile, as a partner in February of 2008. Rob has been an equity analyst in the medical device industry since 1994.
As a Partner on the Private Transactions team at Deerfield, Steve joined Deerfield in 2013 to work on structured transactions in Deerfield’s Private Design Funds.